Vaccine dilemma: To take or not to take Covaxin
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
Category: Serum Institute of India
I would not take Covaxin without efficacy data: Gagandeep Kang
Scientists, manufacturers and drug regulators have been speeding up the timelines to develop, test and approve vaccines for emergency use. Three safe and efficacious vaccines from Pfizer, Moderna and AstraZeneca…
With hasty approval, India squanders an opportunity to build trust in COVID-19 vaccine
Transparency in the approval process is vital for gaining the trust of people so that they don’t hesitate to take the vaccine. If there is already some degree of anxiety…
Why people with prior SARS-CoV-2 infection still need to be vaccinated
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
Why a dry run for COVID vaccination is needed
This is the first time a vaccine to be administered outside the universal immunisation programme and specifically for adults is to be rolled out. Since several aspects of the COVID vaccination programme are new, the government has rightly decided to undertake a dry-run for vaccine administration.
COVID-19: Ethical challenges of vaccinating people with comorbidities
Unlike in other groups, national databases of people with comorbidities are not available. However, though not comprehensive, since 2010, State governments have been conducting population-based district level screening to detect…
Can COVID-19 vaccines with EUA be used at the population level?
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s Bharat Biotech underlines the regulator’s priorities even for emergency use…
